Valneva Rebounds From 2022 Setbacks With Pivotal Success For Chikungunya Jab

The French firm’s vaccine candidate, VLA1553, has passed a Phase III milestone for the mosquito-borne disease – which has no approved options – as it bounces back from a year full of COVID-19-related disappointments.